Cargando…

ACE2, a drug target for COVID-19 treatment?

Detalles Bibliográficos
Autores principales:	Liu, Yang, Huang, Huilian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9192920/ https://www.ncbi.nlm.nih.gov/pubmed/35699908 http://dx.doi.org/10.1007/s11845-022-03055-1

Ejemplares similares

Off‐target ACE2 ligands: Possible therapeutic option for CoVid‐19?
por: Brogi, Simone, et al.
Publicado: (2020)

COVID-19 and Comorbid Hypertension: Is ACE2 the Culprit?
por: Zhang, Ting, et al.
Publicado: (2020)

Obesity and COVID-19: ACE 2, the Missing Tile
por: Iannelli, Antonio, et al.
Publicado: (2020)

ACE polymorphism and COVID-19 outcome
por: Delanghe, Joris R., et al.
Publicado: (2020)

RAAS-Blockade in COVID-19: The Ace of Spades?
por: Agarwal, Krishna A., et al.
Publicado: (2021)

Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19
por: Tsiambas, Evangelos, et al.
Publicado: (2020)

The angiotensin-converting enzyme 2 (ACE2) receptor in the prevention and treatment of COVID-19 are distinctly different paradigms
por: McLachlan, Craig Steven
Publicado: (2020)

Is there an underlying link between COVID-19, ACE2, oxytocin and vitamin D?
por: Diep, Phuoc-Tan
Publicado: (2021)

ACE-inhibitor/angiotensin receptor blockers (ACE-I/ARBs) therapy in COVID-19 infected dialysis patients
por: Daoud, Ahmed, et al.
Publicado: (2021)

Inhibition of endocytic recycling of ACE2 by SARS-CoV-2 S protein partially explains multiple COVID-19 related diseases caused by ACE2 reduction
por: Ren, Yongwen, et al.
Publicado: (2022)

An epidemiological study exploring a possible impact of treatment with ACE inhibitors or angiotensin receptor blockers on ACE2 plasma concentrations
por: Wild, Philipp S., et al.
Publicado: (2020)

Comment on “Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management”
por: Sahin, Mustafa, et al.
Publicado: (2020)

ACE2 mutation might explain lower COVID-19 burden in malaria endemic areas
por: De, Auley, et al.
Publicado: (2021)

High Expression of ACE2 on Keratinocytes Reveals Skin as a Potential Target for SARS-CoV-2
por: Xue, Xiaotong, et al.
Publicado: (2021)

Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation
por: Alshahawey, Mona, et al.
Publicado: (2020)

What Is the Role of Angiotensin-Converting Enzyme 2 (ACE2) in COVID-19 Infection in Hypertensive Patients With Diabetes?
por: John, Thadathilankal-Jess, et al.
Publicado: (2020)

Is the Reason of Increased D-Dimer Levels in COVID-19 Because of ACE-2-Induced Apoptosis in Endothelium?
por: Guler, Nil, et al.
Publicado: (2020)

Interactions between ibuprofen, ACE2, renin‐angiotensin system, and spike protein in the lung. Implications for COVID‐19
por: Valenzuela, Rita, et al.
Publicado: (2021)

Mesenchymal stromal cells coated with anti-ACE2 antibodies might improve efficacy against COVID-19
por: Bakry, Nourhan Saied, et al.
Publicado: (2021)

Lessons From COVID-19, ACE2, and Intestinal Inflammation: Could a Virus Trigger Chronic Intestinal Inflammation?
por: Hanrahan, Timothy P., et al.
Publicado: (2021)

ACEs family genes: Important molecular links between lung cancer and COVID‐19
por: Zhang, Yinjiang, et al.
Publicado: (2021)

Re-Detectable Positive RT-PCR Test Results in Recovered COVID-19 Patients: The Potential Role of ACE2
por: Vargas-Ferrer, Juan, et al.
Publicado: (2020)

Increased plasma ACE2 concentration does not mean increased risk of SARS-CoV-2 infection and increased fatality rate of COVID-19
por: Li, Xueting, et al.
Publicado: (2020)

ACE inhibitor-related angioedema in a COVID-19 patient—a plausible contribution of the viral infection?
por: Kuzemczak, Michał, et al.
Publicado: (2021)

Is There a Link between COVID-19 Mortality with Genus, Age, ABO Blood Group Type, and ACE2 Gene Polymorphism?
por: CHEGNI, Hamid, et al.
Publicado: (2020)

Possible Neurological and Mental Outcomes of COVID-19 Infection: A Hypothetical Role of ACE-2\Mas\BDNF Signaling Pathway
por: Motaghinejad, Majid, et al.
Publicado: (2020)

Bromelain inhibits SARS‐CoV‐2 infection via targeting ACE‐2, TMPRSS2, and spike protein
por: Sagar, Satish, et al.
Publicado: (2021)

Continue ACE inhibitors / ARB’S till further evidence in coronavirus disease 2019 (COVID-19)
por: Bansal, Sandeep, et al.
Publicado: (2020)

ACE1 rs1799752 polymorphism is not associated with long-COVID symptomatology in previously hospitalized COVID-19 survivors
por: Fernández-de-las-Peñas, César, et al.
Publicado: (2023)

Angiotensin-converting-enzyme inhibitors (ACE inhibitors) and angiotensin II receptor blocker (ARB) use in COVID-19 prevention or treatment: A paradox
por: Javanmard, Shaghayegh Haghjooy, et al.
Publicado: (2020)

Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways
por: Dalan, Rinkoo, et al.
Publicado: (2021)

Human pluripotent stem cell-derived functional sympathetic neurons express ACE2 and RAAS components: a framework for studying the effect of COVID-19 on sympathetic responsiveness
por: Wu, Hsueh-Fu, et al.
Publicado: (2022)

Discussion on gemcitabine combined with targeted drugs in the treatment of pancreatic cancer
por: Huang, Jun-Hao, et al.
Publicado: (2023)

ACE polymorphism and diabetic nephropathy
por: Wiwanitkit, V.
Publicado: (2010)

Single-cell transcriptional profile of ACE2 in healthy and failing human hearts
por: Zhou, Yitian, et al.
Publicado: (2020)

COVID‐19 treatment in patients with comorbidities: Awareness of drug‐drug interactions
por: Back, David, et al.
Publicado: (2020)

Drug-drug interaction with oral antivirals for the early treatment of COVID-19
por: Vuorio, Alpo, et al.
Publicado: (2023)

ACE I/D polymorphism and epidemiological findings for COVID-19: One year after the pandemic outbreak in Europe
por: Ristić, Smiljana, et al.
Publicado: (2021)

A natural PKM2 targeting agent as a potential drug for breast cancer treatment
por: Shang, Xin‐Yue, et al.
Publicado: (2022)

Structural insights into the SARS-CoV-2 Omicron RBD-ACE2 interaction
por: Lan, Jun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_79ovgnb0gkgm081lvgoh4kqjme